Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19
Status:
Completed
Trial end date:
2021-09-02
Target enrollment:
Participant gender:
Summary
It is known that the pretreatment with exogenous interferon blocks SARS-CoV-2 infection, but
intervention is much more effective if administered prior to infection. In this study the
primary aim is to investigate 28-day regime of nasal interferon gama use in healthy
participants for COVID-19 and other respiratory infections prevention.